当前位置:主页 > 365bet > 365bet体育在线 > 正文

Corbus Drug Succeeds In Mid-stage Scleroderma Study, Shares

2017-06-19 来源: 责任编辑:avapinkham 点击:

分享到:

cena calominalu By Natalie Grover Nov 14 (Reuters) - Corbus Pharmaceuticals www.f6s.com Holdings Inc strona www said its only drug outperformed a placebo in a mid-stage study involving patients with a form of systemic sclerosis, an incurable http://trianswer.com autoimmune condition caused by abnormal growth of connective tissue. Shares of the Norwood, Massachusetts-based company shot up nearly 125 percent to $13.15 in premarket trading on Monday. The 42-patient trial tested the drug, resunab, against a placebo in patients with diffuse cutaneous systemic sclerosis, the less common form of the rare condition that has a higher risk of death.

Patients on resunab scored an average of 33 percent on an index that evaluates changes in skin sprawd_ teraz hardening, lung capacity and assessments of benefit by patients and physicians, while those on the placebo scored zero after 16 weeks, Corbus said. A score of 20 percent or more is considered clinically meaningful. "No drug has ever shown has shown efficacy in scleroderma," Chief Executive Yuval Cohen told Reuters. "What we've seen here is unprecedented - to get these types of responses in a study that is so short and so small.

" Systemic sclerosis, also called scleroderma, comes from the Greek words for "hard skin" and mostly affects women. The chronic, rheumatic disease affects about 90,000 people in the United States and Europe but its cause is unclear. The disease is characterized by vascular damage and scarring or fibrosis of http://soundation.com/user/Marion83 the www.frikers.com skin, the gastrointestinal tract, heart, lungs and other internal organs.
热门专题 测试内容|
Copyright © 2002-2017 365bet体育在线. 版权所有 Power by DedeCms